The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | LUMINOSITY: Teliso-V in Asian patients with c-Met-overexpressing NSCLC
Hidehito Horinouchi, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, comments on findings from the Phase II LUMINOSITY trial (NCT03539536) of telisotuzumab vedotin (Teliso-V) in patients with c-Met protein-overexpressing, non-squamous EGFR wild-type non-small cell lung cancer (NSCLC). Results from Asian patients demonstrated promising overall response rates (ORR) and a manageable safety profile, with common adverse events including hypoalbuminemia and peripheral neuropathy. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
